I joined Memorial Sloan Kettering in 2000 as a senior medical physicist and am currently an Associate Attending Physicist in the Division of Radiotherapy Physics of the Department of Medical Physics.
My work involves developing and providing quality control for radiation therapy treatment plans. I have expertise in specialized treatment techniques such as respiratory gating and stereotactic radiosurgery, which enhances precision during radiation therapy while sparing healthy tissues surrounding a tumor. I am also actively involved in the clinical process of radiation therapy, from simulation to delivering the final treatment. In addition to my clinical duties, I am the Director of the Quality Improvement Section in the Department of Medical Physics. I also oversee the treatment planning activities across the whole network, maintaining quality and consistency and providing education and clinical support.
Currently, my research focuses on automation of Plan Quality Audits across the network.
I received a PhD in physics from the University of Cordoba in Argentina.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Cesar Della Biancia discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.